News Articles for Richard Hopkins

BlinkLab shares have surged more than 30 per cent on its debut listing on the Australian Securities Exchange.

Investment flows from Perth to fund international projects and companies.

Our board moves wrap includes Tim Davidson, Paul Adams, Jeff McGlinn, Oludare Odumosu, and Richard Hopkins.

The strong growth of the medicinal cannabis industry will need to be supported by research for the sector to take the next step.

Biotech company Zelira Therapeutics has received commitments to raise around $4.6 million from a share placement, while rent.com.au is planning an underwritten $2.9 million rights issue.

Perth-based Zelda Therapeutics has struck an agreement to merge with Ilera Therapeutics that could potentially be worth more than $65 million, as it seeks to grow in the heavily regulated global medical cannabis market.

Beadell Resources has announced a restructure of its management and board.

Dr Richard Hopkins has resigned as chief executive of PharmAust to pursue a senior corporate position in another company.

Perth-based medicinal cannabis specialist Zelda Therapeutics has appointed former Phylogica and PharmAust chief executive Richard Hopkins as its managing director.

Dr Richard Hopkins has been appointed chief executive officer of PharmAust.Swapna Keskar has been appointed company secretary of CoAssets.

Safety and security companies featured heavily in Techboard's top trending startups this past fortnight, with five out of the top ten companies representing the category.

Subiaco-based biotech firm Phylogica has announced plans for a heavily discounted $10 million capital raising to fund development of its cancer treatment programs.

WA biotechs are drowning in a sea of red as yet more negative results are reported.

Phylogica chief scientist Richard Hopkins has been appointed as chief executive officer and a board member, switching roles with Paul Watt.

Perth-based biotechnology company Phylogica has appointed Richard Hopkins chief executive officer as part of wider management changes aimed at pursuing work opportunities with other research c